New Direct-Acting Antivirals for Patients with Chronic HCV Infection: Can We Monitor Treatment Using an HCV Core Antigen Assay?

Abstract We evaluated the diagnostic usefulness of an HCV core antigen (HCV-Ag) assay in HCV-infected patients undergoing treatment with direct-acting antivirals. We analyzed 103 samples from 28 patients. Compared with RT-PCR, sensitivity was 96.2% and specificity was 100%. The correlation between t...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic microbiology and infectious disease 2017-03, Vol.87 (3), p.243-246
Main Authors: Alonso, R, Pérez-García, F, Ampuero, D, Reigadas, E, Bouza, E
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens, Viral - immunology
Antiviral Agents - therapeutic use
Automatized systems
Correlation
Direct-acting antiviral agents
Female
HCV core antigen
Hepacivirus - drug effects
Hepacivirus - immunology
Hepatitis C virus
Hepatitis C, Chronic - diagnosis
Hepatitis C, Chronic - drug therapy
Humans
Immunoassay - methods
Infectious Disease
Internal Medicine
Male
Middle Aged
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Sensitivity and Specificity
Viral Core Proteins - immunology
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We evaluated the diagnostic usefulness of an HCV core antigen (HCV-Ag) assay in HCV-infected patients undergoing treatment with direct-acting antivirals. We analyzed 103 samples from 28 patients. Compared with RT-PCR, sensitivity was 96.2% and specificity was 100%. The correlation between techniques was excellent (Pearson coefficient: 0.871). HCV-Ag proved to be useful in patients with sustained viral response and in patients who experienced treatment failures.
ISSN:0732-8893
1879-0070
DOI:10.1016/j.diagmicrobio.2016.11.010